Add BrightSurf on Google Email

Massachusetts General Hospital


New approach for delivery of anti-HIV antibody therapy shows promise in phase I clinical trial

A phase I clinical trial demonstrated the safety and efficacy of a novel adeno-associated viral vector-based treatment for HIV, producing measurable amounts of a broadly neutralizing antibody. The treatment showed wide-ranging clinical implications for potentially preventing or treating HIV and other infections.

SourceMassachusetts General Hospital·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateApr 11, 2022

Diversity in U.S. medicine is not keeping pace with population changes, analysis finds

Despite increasing racial and ethnic diversity, US academic medical programs have underrepresented minority groups, with only modest increases in representation over the past four decades. Female representation has increased significantly, but progress in promoting diversity at leadership levels remains stagnant.

SourceMassachusetts General Hospital·JournalNew England Journal of Medicine·TypeData/statistical analysis·DateApr 6, 2022

HIV drug stabilizes disease progression in metastatic colorectal cancer

A clinical trial reveals that lamivudine, a widely used HIV treatment, halted disease progression in 28% of patients with fourth-line metastatic colorectal cancer. The study suggests an unexpected promising direction for cancer treatment and encourages the exploration of pairing reverse transcriptase inhibitor therapy with immunotherapy.

SourceMassachusetts General Hospital·JournalCancer Discovery·TypeRandomized controlled/clinical trial·DateApr 5, 2022

Molecules produced by cells in response to stress may be indicators of various diseases

Researchers at Massachusetts General Hospital have discovered that certain RNA molecules called tDRs released by cells in response to stress can serve as markers of cellular stress in different diseases. The study created an atlas of stress signatures for tDRs, which can be used to diagnose and understand various conditions.

SourceMassachusetts General Hospital·JournalAdvanced Science·TypeExperimental study·DateApr 5, 2022

Large study challenges the theory that light alcohol consumption benefits heart health

A large study published in JAMA Network Open found no evidence that light alcohol consumption provides heart-related health benefits, instead suggesting lifestyle factors common among moderate drinkers contribute to the observed benefit. The study linked high-risk cardiovascular disease across all levels of alcohol intake.

SourceMassachusetts General Hospital·JournalJAMA Network Open·TypeData/statistical analysis·DateMar 25, 2022

Fundamental cancer metabolism dogma revisited

Researchers at Massachusetts General Hospital discovered that non-dividing colon cancer cells employ Warburg glycolysis to reduce toxic reactive oxygen species accumulation. This adaptation challenges the long-held dogma of the Warburg effect, highlighting the need for single-cell level analysis tools.

SourceMassachusetts General Hospital·JournalNature Communications·TypeExperimental study·DateMar 22, 2022

Marijuana for medical use may result in rapid onset of cannabis use disorder

Researchers at Massachusetts General Hospital found that medical marijuana users were more likely to develop cannabis use disorder (CUD) than expected, particularly those seeking relief from anxiety and depression. The study suggests that the current system of dispensing and using medical marijuana may be contributing to this issue.

SourceMassachusetts General Hospital·JournalJAMA Network Open·TypeRandomized controlled/clinical trial·DateMar 18, 2022

Study identifies key barriers to innovation among medical trainees

A new survey conducted by Massachusetts General Hospital researchers reveals that medical students, residents, and fellows do not see themselves as innovators. The study identifies key impediments to innovation, such as limited time and energy, lack of physical resources, and expertise gaps, but also highlights potential solutions like...

SourceMassachusetts General Hospital·JournalNature Biotechnology·TypeSurvey·DateMar 16, 2022

Study reveals how to activate the immune system’s natural killer cells to protect against cancer and other diseases

Researchers at Massachusetts General Hospital have found that specific proteins surrounding organs and tissues can suppress natural killer cell function. Blocking these interactions could potentially reactivate the cells, providing a new strategy for treating various health conditions, including cancer, autoimmune diseases, and inflamm...

SourceMassachusetts General Hospital·JournalScience Advances·TypeExperimental study·DateMar 16, 2022

Sequencing of drug combinations could amplify the anti-tumor immune response in liver cancer

Researchers found that sequencing drug combinations can enhance the anti-tumor immune response in liver cancer, potentially reducing toxic drug exposure. The new strategy primes the tumor with an immune checkpoint inhibitor before using a multikinase inhibitor, enhancing its effectiveness.

SourceMassachusetts General Hospital·JournalJNCI Journal of the National Cancer Institute·TypeExperimental study·DateMar 15, 2022

Lower, more frequent doses of nanomedicines may enhance cancer treatment

Researchers at Massachusetts General Hospital found that using nanomedicines at lower, more frequent doses can normalize the tumor microenvironment and improve cancer treatments. The study showed that this approach can help correct abnormalities that protect tumors and improve blood vessel function and immune activation within a tumor.

SourceMassachusetts General Hospital·JournalJournal of Controlled Release·TypeExperimental study·DateMar 11, 2022

New research findings could help improve bone marrow and stem cell transplantation for patients with blood-related diseases

Scientists have discovered the signature of genes expressed by hematopoietic stem cells that can produce healthy blood cells after being transplanted. This finding could enable scientists to expand these cells outside the body or convert other types of stem cells into functional blood cells.

SourceMassachusetts General Hospital·JournalNature Communications·TypeExperimental study·DateMar 1, 2022

Researchers identify a promising drug for treating serious COVID-19 complication in children

Researchers have identified larazotide acetate as a promising treatment for multi-inflammatory syndrome in children (MIS-C), a rare but severe condition. The study showed rapid improvement in symptoms and faster resolution of gastrointestinal issues among children treated with the drug, suggesting its potential as an adjuvant therapy.

SourceMassachusetts General Hospital·JournalCritical Care Explorations·TypeRandomized controlled/clinical trial·DateFeb 23, 2022

Are pandemic-related stressors impacting uninfected people’s brain health?

A new study from Massachusetts General Hospital found that living through the COVID-19 pandemic can lead to brain inflammation and symptoms like fatigue, concentration difficulties, and depression in uninfected people. The research suggests that societal and lifestyle disruptions during the pandemic may trigger this inflammatory response.

SourceMassachusetts General Hospital·JournalBrain Behavior and Immunity·DateFeb 22, 2022

Researchers restore function in a gene that can suppress liver cancer and enhance immunotherapy

A team of researchers has reprogrammed the tumor microenvironment of liver cancer by using mRNA nanoparticles, restoring the function of the p53 master regulator gene. The approach increased antitumor immune responses in hepatocellular carcinoma laboratory models and shows promise for treating HCC and other cancers.

SourceMassachusetts General Hospital·JournalNature Communications·TypeExperimental study·DateFeb 9, 2022

Most people with prior SARS-CoV-2 infection or vaccination have T cell immune responses against Omicron variant despite low antibody responses

A recent study published in Cell found that T cell responses are still robust against the Omicron variant in most individuals with prior SARS-CoV-2 infection or vaccination, offering protection against severe disease. Booster vaccines can enhance T cell responses, substantially increasing immunity against severe COVID-19.

SourceMassachusetts General Hospital·JournalCell·TypeObservational study·DateFeb 9, 2022